Target intelligence / Profile preview

Haemophilus influenzae type b polyribosyl-ribitol-phosphate conjugated to tetanus toxoid (PRP-T)

Target: PRP-T
Molecular classification: Vaccine, Conjugate vaccine, Polysaccharide-protein conjugate

Overview

Haemophilus influenzae type b polyribosyl-ribitol-phosphate conjugated to tetanus toxoid is a conjugate vaccine designed to prevent invasive diseases caused by Hib bacteria. The vaccine consists of the capsular polysaccharide from Hib—polyribosyl-ribitol-phosphate (PRP)—covalently linked to inactivated tetanus toxoid protein. This conjugation process converts the poorly immunogenic PRP into a T-cell dependent antigen, enhancing immune recognition and inducing robust antibody responses, especially in infants. It is highly effective in reducing the incidence of severe Hib infections through routine childhood vaccination programs.

Other names: Hib conjugate vaccineActHIBHiberixOmniHIBHaemophilus influenzae type b vaccine

Mechanism of action

Induces anti-PRP antibodies through T-cell dependent immune response, providing protection against Haemophilus influenzae type b.

Biological functions

Active immunizationInduction of antibody responseImmunological memory

Disease associations

Prevention of Haemophilus influenzae type b infectionsPrevention of meningitisPrevention of pneumoniaPrevention of epiglottitisPrevention of sepsis

Safety considerations

Injection site painFeverRare allergic reactions

Beyond the preview

Go deeper on Haemophilus influenzae type b polyribosyl-ribitol-phosphate conjugated to tetanus toxoid (PRP-T).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Haemophilus influenzae type b polyribosyl-ribitol-phosphate conjugated to tetanus toxoid (PRP-T).

Explore the full profile